Creating a new imaging agent to better detect pancreatic cancer
Development of a PET CCR2 Imaging Agent to Profile PDAC Microenvironment
This study is testing a new imaging tool that helps doctors spot early signs of pancreatic cancer by looking at the tumor's surroundings, which could lead to quicker diagnoses and better treatment options for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10943827 on NIH RePORTER |
What this research studies
This research focuses on developing a new imaging agent that utilizes positron emission tomography (PET) to identify and profile the microenvironment of pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer. The study aims to improve early detection of small tumors, which is crucial for effective treatment and better survival rates. By targeting specific immune cells within the tumor environment, the imaging agent could provide insights into tumor progression and treatment resistance. Patients may benefit from more accurate imaging techniques that could lead to earlier diagnosis and intervention.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for pancreatic ductal adenocarcinoma or those with early-stage pancreatic tumors.
Not a fit: Patients with advanced pancreatic cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved early detection of pancreatic cancer, significantly enhancing treatment outcomes for patients.
How similar studies have performed: Other research has shown promise in using imaging agents for cancer detection, suggesting that this approach could be effective.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Goodman, Mark Myron — Emory University
- Study coordinator: Goodman, Mark Myron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.